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INTRODUCTION
EGFRvMII is a tumor specific, ligand-independent, constitutively active variant of the epidermal growth factor receptor (1) (2) (3) (4) (5) (6) (7) . Its expression has been detected in gliomas and various other human malignancies, including breast cancer (8) (9) (10) (11) (12) (13) (14) (15) ). However, no detectable level of EGFRvIII has been observed in adult tissues, including normal breast tissues (12, 15) .
This is a final report of grant DAMD17-99-1-9206. In the original proposal, we proposed three aims; 1) To determine the expression of EGFRvIII and correlation with clinicopathological prognostic factors in human breast cancer specimens; 2) To test the hypothesis that over-expression of EGFRvIII is capable of increasing the malignancy and metastatic potential of breast cancer cells; and 3) To test the hypothesis that downregulation of EGFRvIII expression in breast cancer cells will reduce the tumorigenicity.
We have completed all the proposed aims and we have published two manuscripts. In this final report, we will summarize and out line the research findings. Detailed descriptions please see the attached two manuscripts. In addition to these two manuscripts, we also examined the frequency of EGFRvIII protein expression immunohistochemically in over seven hundred primary breast cancer specimens with a specific EGFRvIII mAb on both tissue microarray and paraffin embedded specimens. The following, we described the findings for the immunohistochemical analysis study. Table 1 , the invasive tissues from each institution have similar distributions of expression levels for EGFRvUI. Table 1 clearly indicates that EGFRvIII expression is associated with disease progression. The statistical analysis indicates the expression of EGFRvIJ associated with more malignant breast tumors remains significant, as shown in Table 1 disease status increases. It is noteworthy (Strikingly), 88% (9/11) of lymph node specimens expressing EGFRvII. This indicates that EGFRvilI expression is strongly associated with breast cancer progression. S ince, Manitoba is the only institution that provided samples from all tissue types. The numbers of samples for each expression level from the Manitoba tissues alone are displayed in Table 2 . EGFRvJIL is significantly associated with increasing invasiveness (p < 0.0001) with positive expression occurring in no samples (0%) of normal tissue, 18 DCIS samples (47%), and 74 (76%) of the invasive cancer samples. Also notice specifically that the percentages of weak positive and positive increase with disease progression. 'Percentages did not include samples that were not readable.
BODY
High frequency of EGFR VIII expyression in human primary breast cancer specimens
Lombardi Cancer Center (LCC)
Manitoba (MAN)
3. National Institute of Health (NIH) EGFRvHI expression inversely, correlated with PR status in breast carcinoma ER and PR status are known prognostic or predictive factor in invasive breast carcinoma; we were interested to evaluate the correlate of EGFRvIII expression with ER and PR. Because, we did not obtain the ER/PR data from the set of NIH tissue micro array samples, we evaluated total of 137 cases from LCC and Manitoba samples. Table 3 provides the statistical analysis of ER and PR status and their association with EGFRvIII status. As illustrated in 
Taken all together, a remarkable aspect of this present study is that we found that • Detailed descriptions please see attached two manuscripts.
REPORTABLE OUTCOMES
We have published two manuscripts and three abstracts resulted from the award.
Copies of these manuscripts are included in the appendix of this final report. By applying this technique, we were able to preferencell line resulted in a 3-fold Increase in colony formation and tially select "pure" breast cancer cells from mixed cell populations significantly enhanced tumorigenicity in nude mice (p < of breast tissues for genetic study. As a result, we detected a high 0.001). EGFRvIII could also Induce ErbB-2 phosphorylation.
incidence (67.8%) of EGFRvmII transcripts in primary invasive The existence and significance of EGFRvIII transcript in hu-breast cancers by LCM but not in normal breast tissue. These man breast cancer, however, was not reported. In our study, results confirmed the presence of EGFRvIlI in human breast we detected the presence of EGFRvIII mRNA and revealed a cancer. We believe that these findings will have significant implihigh Incidence (67.8%) of EGFRvIII transcript in human pri-cations in breast cancer research, diagnosis, and treatment. by using TA Cloning kit (Invitrogen, Carlsbad, CA). The cloning reaction includes 1 pi! of vector, 5 p.l of RT-PCR product, 1 p.l of T4 ligase and 1ox ligase buffer and the total volume adjusted to from a 42-year-old woman was used to determine whether or not 10 p1 for 16'C, over night. The product was transformed into E. EGFRwt or EGFRvIII were expressed. Figure 2b depicts the coli competent cells and mini-plasmid preparation was performed. normal breast tissue to express neither wildtype nor mutant form of Sequence analysis was done in automated sequencer with T7-EGFR. primer.
In these 28 cases of invasive breast cancer specimens, we Imnunohistochemistry observed some to express EGFR wt mRNA only, and others to express the mutant form EGFRvIII. Interestingly, a majority of Paraffin-embedded sections of primary invasive tumors were breast cancer tissues detected both mutant and wildtype EGFR deparaffinized in xylene for 5 min. For frozen sections, acetone mRNA in the same tumor. Figure 2c demonstrated representative was used for fixation. After a brief rinse in I X phosphate-buffered results of the invasive breast carcinoma tissue samples for saline (PBS), the specimens were then subjected to staining. Two EGFRwt mRNA only (Case 200), mutant form EGFRvII (Case different specific antibodies were used for our study. One of them 531) and coexpression of EGFRIEGFRvLII (Cases 657 and 680). is specific for wildtype EGFR (Ab-3, Neomarker, CA) for frozen These results indicate the presence of a heterozygote of this section only and the other one is specific for EGFRvUI (Ab-18, receptor in breast cancer. The heterozygotes displayed varied Neomarker) for paraffin section only. Their specificity were as-intensities in both wildtype and mutant forms. Table I 
RESULTS
EGFRvIH sequence with a 801 bp deletion in the extracellular
Laser capture of breast cancer cells ligand binding domain, creating a glycine at the splicing position In our study, a total of 28 cases of primary invasive breast as that noted in human glioblastoma (Fig. 2de ). cancers were subjected to LCM/RT-PCR analysis. Breast cancer Detection of EGFRvIII and EGFR protein coexpression in cells were captured from breast cancer tissues by laser transfer breast cancer from modified hematoxylin-eosin (HE) stained specimens. Figure  1 illustrates laser transfer of breast cancer cells from 2 represenThe same set of primary invasive breast cancer specimens, tative cases. Case 1 (Fig. la-c) is a poorly differentiated breat subjected to LCM/RT-PCR studies, were used to assess the protein carcinoma, and the cancer cells infiltrated into normal stroma levels of EGFRwt and EGFRvIn by immunohistochemical (IHC) network. LCM was able to successfully microdissect the individual analysis. We have characterized a specific EGFRvII (Ab-18) cancer cells from tumor tissue. For Case 2 ( Fig. ld-J) , a nest of monoclonal antibody. As shown in Table IM antibody EGFRvIII infiltrated cancer cells surrounded by non-tumor tissue were trans-(Ab-18) specific recognizes EGFRvIII but not the wildtype EGFR ferred. Thus, LCM specifically captures only the cancer cells and protein. In addition, this antibody does not cross react with other avoids the surrounding stroma elements.
EGF-family receptors (Table 11) . Therefore, this specific antibody was used for all the immunohistochemical analysis studies in our Identification of EGFRvII and coexpression of EGFRIEGFRvlIl study. We also characterized a panel of commercially available mRNA in breast cancer tissues EGFR antibodies. EGFR (Ab-3) monoclonal antibody appears The laser captured cancer cells were subsequently subjected to only recognizes the wildtype EGFR but not the EGFRvIII receptor. RNA isolation, followed by reverse transcription and nested PCR This EGFR (Ab-3) does not cross react with other EGF-family amplifications. A control experiment was performed to verify the receptors (Table II) . specificity of the primers for PCR amplification (Fig. 2a) . RNAs A total of 21 cases of frozen sections of breast cancer tissues from our previous EGFR and EGFRvMII transfected hematopoietic were available for determination of EGFRwt expression with this cells (32D cells), as well as EGFRvII transfected human breast well-characterized specific anti-EGFRwt monoclonal antibody cancer cell line MCF-7 cells were used as positive controls.
15 RNA (Ab-3). As summarized in Table mI, EGFR wt expression was from ErbB-2 and ErbB-3 cotransfected 32D cells was used as detected in 61.9% (13/21) specimens of primary invasive breast negative control. As expected, the wildtype EGFR mRNA dis-cancers, most of which displayed membrane immunoreactivity of played a 1026-bp fragment and the EGFRvIn mRNA displayed a variable intensities (Fig. 3a) . There wasino cytoplasmic reactivity shortened 225-bp fragment. No PCR products were detected from noted in EGFRwt staining. The same set of mirror image paraffin ErbB-2+ErbB-3 transfected 32D cells. A normal breast tissue embedded tissues was also used to analyze EGFlIvT1I expression was detected in 57.8% (11/19) specimens (Table I1) . EGFRvIII, however, displayed an intracellular localization in contrast to the plasma membrane location of the wildtype EGFR (Fig. 3b) . OverFIGuRE 2 -(a) A control experiment for EGFRvIII and EGFR in cell all, the immunostaining results were in concordance with LCM/ lines. RNAs isolated from EGFRvII and EGFR transfected 32D cells, RT-PCR data (Table IV) . Comparing the wildtype EGFR mRNA as well as EGFRvII transfected MCF-7 cells were used as positive controls. RNAs isolated from ErbB-2 and ErbB-3 cotransfected 32D to EGFR protein, 14 of 21 cases were exactly matched (Table IV) . cells were used as a negative control. RT-PCR and nest PCR were Six out of 21 wildtype cases were detected only at the mRNA performed for these samples. As illustrated in this ethidium bromide level, but no increased protein content by immunological evalua-gel, the EGFR mRNA (1026 bp) and EGFRvIII mRNA (225 bp) was tion. A similar observation resulted from the comparison of EGFR-detected in EGFR and EGFRvIH transfected 32D cell lines, respecviii mRNA to EGFRvIII protein (Table IV) Despite the high frequency of EGFRvIII expression in primary LCM/RT-PCR, but relatively faint or no obvious staining by IHC invasive breast cancer specimens, we observed that most of these analysis. It is reasonable that LCM/RT-PCR is more sensitive than cell lines express EGFRvHI in vivo, but not it in vitro. In vitro, the' immunostaining (Table III) , because polymerase chain reaction is cells were cultured in IMEM, supplemented with 10% FBS and a very efficient method in amplifying gene, whereas immunohis-1% glutamine at 37°C, 5% CO 2 incubator as published elsewhere. tochemistry detection only reveals the protein, which is overex-Obviously, it is not due to technical problem in culture. Similar pressed. There are 2 cases showing discrepant results (Cases 283 findings were also reported in human glioblastoma. Virtually, all and 312). We are not sure of the reason for these discrepancies. cell lines derived from primary glioma tumor lose EGFRvHI Reports from early studies regard the EGFR overexpression in expression in tissue culture. 22 It was suggested that either a growth human breast cancer varies between 15-90%. As we now know disadvantage in vitro or a selection for EGFRvHI overexpression that most commercially available antibodies to EGFR are able to in vivo. 23 It is very possible that there are some critical factors, recognize both wildtype and mutant EGFR that raises a concern on which might facilitate the EGFRvIII expression in vivo, but that the antibody selection. Therefore, some previous publications on are Missing in vitro. the interpretations of EGFR overexpression in breast cancer may It has been well documented that the EGFRwt is a membrane be questionable, in which the overexpression may only attribute to receptor, 24 whereas EGFRvIH mainly expresses in the cytoplasmic the wildtype EGFR, and the detection of EGFRvIII was over-in breast tumor tissues. Similar observations have been reported in looked. In brain tumor, it was found that EGFR overexpression human glioblastoma tumors, where EGFRvlII is expressed excluwas associated with a mutant form of EGFR,°0.' 1 with the most sively in the cytoplasm. 25 As shown in Figure 3 , the EGFRwt common mutant form of EGFRvmI. 2 1 These results support our displays a membrane staining, whereas the EGFRvHII exhibits a present findings. Although the double staining is not available in predominantly cytoplasmic staining and some nuclear staining as our study due to the limitation in the application of antibodies, our well in primary invasive breast cancer tissues. The altered subcel-LCM/RT-PCR result is a strong support for co-presence of EGFR-lular location of EGFRvfII in breast cancer may suggest that the vIii and EGFR. Hence, our present studies provide information trafficking, signaling, recycling, as well as degradation of the that spontaneous alteration of EGFR mRNA occurs in the breast mutant receptor may somehow differ from its wildtype form and cancer. The coexistence of EGFR and EGFRvIII in cancer cells leads to cytoplasmic location. The changed subcellular location may reflect transitions or progressions of tumor behavior. To our may attribute to a sustained tyrosine kinase activity, which manknowledge, this is the first observation for EGFRvlII/EGFRwt ifests a more potent, aggressive and oncogenic effect in human coexpressing in breast cancer, cancer. Recent report also indicated that EGFRvIII receptor-recep-tor self-association is highly dependent on a conformation induced EGFRwt and EGFRvIII mRNA and protein are frequently detected by N-linked glycosylation. Ligand-independent dimerization of in human primary invasive breast cancer. No detectable levels of the EGFRvII is contingent upon core glycosylation.26 Phospho-EGFRvIII were detected in a normal breast tissue, which was rylation-induced conformation change results in exposure of se-tested. Although our samples are limited, the high percentage of quence motifs involved in endocytic and lysosomal sorting and EGFRvIII expression may implicate its possible role in the pathosuch unmasking is thought to be obligatory for receptor downregugenesis of breast cancer. In addition, we successfully amplified >1 lation.27 Further functional and biological analysis, as well 'as kb fragments by LCM/RT-PCR, thus extending the fragment limit trafficking and signaling is likely to provide comprehensive in-size reported by utilizing LCM/RT-PCR technology. Considering sights for the role of EGFRvmI in breast cancer, the high frequency of this receptor alteration, as well as the unique LCM is a powerful technology. It exclusively obtained the pure distributions of the receptor makes it a compelling target for breast cancer cells from mixed cell populations of breast tissues, therapeutic strategies without interfering with normal signaling.
Other techniques, such as Southern or Northern Blotting and RNA We believe that our study provides useful information on molecprotection assay will only provide the information from whole ular genetics and potential target for breast cancer. breast tissue, but not from pure cancer cells, which may make it difficult to interpret result. This issue is avoided by LCM selection for exclusive malignant cell, and the result is more accurate. In ACKNOWLEDGEMENT addition, because RNA is likely to be degraded through prolonged exposure at room temperature after a series of experimental pro- . We thank Dr. ME. Lippman for helpful fragments around 500 bp. 19 . 20 . 27 In contrast, we successfully am-discussions and we express our appreciation to Dr. A. Hayes for plified a 1026-bp fragment, whose fragment size is relatively technical suggestion in laser capture microdissection. Figures 1-3 EGFRvIII is a tumor specific, ligand-independent, constitu-cells results in inhibition of proliferation, and reduction of tumor-* tively active variant of the epidermal growth factor receptor. igenicity in athymic nude mice. Furthermore, this ribozyme has no Its expression has been detected in many human malignan-effects on the expression of EGF-family receptors and proliferales including breast cancer. No detectable level of EGFRvII tion in MCF-7JLCC2 breast cancer cells, which do not express has, however, been observed in adult tissues, including nor-EGFRvTI but express wild-type EGFR and other EGF-family mal breast tissues. These unique features of the EGFRvIII make it an excellent target for biologically based therapies. receptors. These results suggest that we have generated a tumorWe have designed and generated a tumor specific ribozyme specific biologically functional ribozyme and further demonstrate targeted to EGFRvIII. This specific EGFRvIII ribozyme is able that EGFRvIII plays a significant role in breast cancer cell prolifto effectively cleave EGFRvIII mRNA under physiological eration. conditions in a cell-free system, but does not cleave wild-type EGFR and other EGF-family receptors. While expressing this EGFRvIII-ribozyme in breast cancer cells, EGFRvlII.ri-MATERIAL AMD METHODS bozyme is capable of downregulating endogenous EGFRvIII Cell lines and cell culture expression at the mRNA and protein levels. Inhibition of proliferation was observed in EGFRvlll-ribozyme transfec-MDA435/LCC-6, MCF-7ILCC-216. 17 were generously provided tants. In addition, downregulation of EGFRvIII in breast can.
by R. Clarke (Georgetown University Medical Center). MCF-7/ cer cells significantly inhibited tumor growth In athymic nude EGFRvAII breast carcinoma cell lines1 2 and their derivatives were mice. Furthermore, this ribozyme has no effect on EGF-maintained in I1MEM (Cellgro), supplemented with 10% FBS family receptor expression or the proliferation of breast can-(Biofluids, Rockville, MD). cer cells, which do not express EGFRvIII but express wildtype EGFR and other EGF-family receptors. These results Generation of EGFRvIIJ ribozyme suggest that we have generated a tumor-specific, biologically functional ribozyme and further demonstrate that EGFRvIII
We selcted the ribozyme target site the novel junction sequence plays a significant role in breast cancer cell proliferation. The of EGFRvlTI mRNA, 5'-AAGAAAGGUAAUUAUGU-3', where ultimate goal of this approach is to provide a potential treat-underlined nucleotides comprise the novel cleavage site for this ment for breast cancer by specifically targeting this receptor. 
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We then carried out in vitro run-off transcripts from an EGFR-Anchorage-dependent growth assays viii cDNA construct to generate the EGFRvHII ribozyme substrate.
Cells were harvested using trypsin, and 3,000 cells/well were Likewise, EGFRvIH-ribozyme was chemically synthesized as plated in 24-well plates (Costar, Cambridge, MA). All samples DNA oligonucleotide and subsequently synthesized in vitro by were prepared in triplicate. Cells were counted in a Coulter using the T7 RNA polymerase. Cleavage reactions were carried Counter (Beckman Coulter, Inc., Palo Alto, CA) on Day 1 (the out in 50 mM Tris-HCL (pH 8.0) and 20 mM MgC1 2 , Substrate following day), and Days 3 and 7. Values indicate the mean of and ribozyme transcripts were then mixed and incubated at 50'C triplicate determinations. for 30 min. Reaction products were analyzed on 6% urea polyacrylamide gel and products were detected by autoradiography.
Anchorage-independent growth assays A bottom layer of 1 ml of IMEM containing 0.6% agar and 10% Transfection FBS was prepared in 35-mm tissue culture dishes. After the bottom Cells (1 X 106) and 10-15 R.g of plasmid DNA were used for layer solidified, cells (10,000/dish) were then added in a 0.8 ml top each transfection. Transfection was carried out using the Calcium layer containing 0.4% Bacto Agar and 5% FBS. All samples were Phosphate Transfection System (Invitrogen, Carlsbad, CA), ac-prepared in triplicate. Cells were incubated for 10 days at 37 0 C. cording to the manufacturer's protocol. The cells were then se-Colonies larger than 60 pam were counted on a cell colony counter lected in a growth medium containing appropriate amounts (350 (Ommias 3600; Imagine Products Inc., Carmel, Indiana). pg/ml) of Geneticin (G418-sulfate; Invitrogen).
In vivo studies
Autophosphorylation of EGFRvIII
Four-to 6-week-old female athymic nude mice were inoculated The cells'were serum starved overnight at 37°C prior cell lysis. into the mammary fat pat with MDA435/LCC6/wt, MDA435/ Cells were lysed in HEPES lysis buffer (50 nM HEPES, 150 mm LCC6/vector, as well as EGFRvIl1 ribozyme-transfected clones, NaCl, 10% glycerol, 1% Triton X-100, 1.5 mM MgCl 2 , and 1 mM LCC6/RzC1 and LCC6/RzC9. Tumor size was measured twice EGTA), and the cell debris was pelleted by centrifugation-" 4 weekly and calculated by measuring tumor volume (length X The lysates were then subjected for immunoprecipitation with width X thickness). When tumor volumes reached up to 270 ± SD anti-EGFRvIU (NeoMarker, Union City, CA), in combination with mm, 3 , mice were sacrificed. Xenograft tumors were surgically Protein A-Sepharose CL-4B (Amersham Pharmacia, Sweden) removed and snap frozen for Western blotting analysis of EGFRovernight at 41C with gentle agitation. Immunoprecipitates were vMI expression. then separated by SDS-PAGE and transferred to nitrocellulose. Statistical analysis. Bound proteins were immunoblotted with anti-phosphotyrosine monoclonal antibody (Upstate, Lake Placid, NY), followed by A general estimating equation (GEE) procedure 22 was impleblots with 0-5 pg/ml of secondary antibody linked to horseradish mented to determine if the growth rate were different among the peroxidase. Immunoreactive bands were detected with an en-groups for the anchorage-dependent assay. The cell counts data hanced chemiluminescence reagent (ECL; Amersham).
were transformed by natural logs to conform to normality assumptions. For the anchorage-independent assay, the differences in Fluorescence-activated cell sorter (FACStar) analysis colony numbers were tested using a 2-way analysis of variance, 23 Cells (1 X 106) were harvested and then stained for 1 hr with with colony size and group as the factors. In addition, a Kruskalanti-EGFR (Ab-1) monoclonal antibody (NeoMarker) or anti-Wallis test24 was carried out to determine whether the groups EGFRvHII monoclonal antibody (Ab-18) (NeoMarker), or ErbB-2, differed in the proportion of colonies growing into different size ErbB-3 (c-17) and ErbB-4 (c-18) (Santa Cruz Biotechnologies, group. For in vivo studies, a nested analysis of variance test was Santa Cruz, CA) at 4°C. Stained cells were then washed with cold carried out to assessing the differences in tumor size. PBS. A secondary FITC-anti-mouse antibody was used, and the expression levels of EGFRvmI, as well as other EGF-family re-RESULTS ceptors in each cell lines were quantitatively measured by flow Generation and demonstration of EGFRvJII ribozyme efficacy cytometry.
and specificity in a cell-free system Semiquantitative PCR to assess EGFRvIII mRNA expression The unique characteristics of EGFRvIII receptor make it an attractive candidate as therapeutic target Specifically, the deletion The primers used for PCR were 5'-ATGCGACCCTCCGG-junction of EGFRvIII creates a new amino acid glycine via a was carried out in 50 ILI volume with T U of Tai DNA polyimerase unique GUA sequence that serves as a novel natural targeting site wascariedoutin 0 p1 vlum wih l ofTaqDNApolmerse for hammerhead ribozyme. We designed a hammerhead ribozyme at 94°C for 45 sec, 52°C for 60 sec and 72 0 C for 90 sec. A series targeted t isovel We desite withinerhe rio m of PR smpls wre hencolectd a difernt ycls, ollwed targeted to this novel fusion junction site within the EGFRvIHf of PCR samples were then collected at different cycles, followed mRNA (Fig. 1 ). This EGFRvIII ribozyme should only cleave by a final extension step at 72 0 C for 15 rain. EGFRvEII mRNA but not the wild-type EGFR. The catalytic Total cellular RNAs from ribozyme transfectants were isolated activity of experimental and control ribozymes was first evaluated using TRIZOL Reagent (Invitrogen). Equal concentrations of in an extracellular system. As illustrated in Figure 2 , this EGFR-RNA were then subjected to RT with random primers. Total RNA vMI ribozyme can cleave EGFRvMI mRNA precisely and effiderived from MDA435/LCC6Iwt and MCF-7/LCC2/wt cells were ciently under physiological conditions in a cell free system. Cleavused as controls. The resulting cDNAs were amplified on semi-age was specific as the actual sizes of the cleaved fragments quantitative PCR by the primers for the respective construct and corresponded to the expected sizes, when cleavage occurred im-GAPDH as an internal control (reference gene). mediately 3' to the GUA sequence. As an efficacy control, catalytically inactive mutant ribozyme was engineered. The point Northern blot analysis mutation of G-A in the catalytic domain of this EGFRvlII riTotal RNA was extracted from the cells using TRIzol reagent bozyme results in a loss of catalytic activity, as predicted by the (Invitrogen) followed by isopropanol precipitation. The RNA con-mutational studies of McCall et al. 15 (data not shown). We also centration was determined by measuring absorbance at 260 nm. tested the specificity of this EGFRvLII ribozyme by using the Ten micrograms of total RNA was electrophoresed on formalde-wild-type EGFR mRNA as a substrate. As expected, no cleavage hyde containing 1% agarose gel and transferred the RNA onto a was observed by this ribozyme (data not shown). These results nylon membrane.
32 P-labeled EGFRvIH DNA probe was used for indicate that the GUA sequence that chosen in the novel fusion hybridization. 18S rRNA was used as an internal control (loading junction of EGFRvLII mRNA is accessible to ribozyme mediated control).
cleavage in an extracellular system.
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A C A U C. reduced protein levels in EGFRvIm-Rz transfected cells. Two micrograms of cell lysates were immunoprecipitated with a specific antiEGFRvIm antibody. Precipitated proteins were then subjected to WestIntracellular model system for studying the specificity and em blotting with an anti-phosphotyrosine antibody. d: Northern efficacy of EGFRvIII ribozyme analysis of EGFR mRNA expression, 28S RNA was used as loading We next investigated the catalytic activity of these ribozymes control. e: FACS analysis of EGFR expression with anti-EGFR antiintracellularly. The complexity of heterodimerization and trans-body. phosphorylation between the EGF family receptors in breast cancer cells makes it difficult to determine the specificity of this EGFRvmI ribozyme. Furthermore, the action of this ribozyme is to 7/EGFRvIII to examine the intracellular efficacy and efficiency of interrupt EGFRvIII gene expression. One of our early studies have this EGFRvIII ribozyme and MCF-7/LCC2 was used as a control demonstrated that the expression of EGFRvLII in MCF-7 human to test the specificity of this EGFRvIm ribozyme. breast cancer cells induced cell proliferation and enhanced tumorigenicity in nude mice. 12 We selected 2 cell lines, MCF-7/EGFRWe constructed this EGFRvIIn ribozyme in a mammalian exvIi and MCF-7/LCC2, as our model systems. MCF-7/EGFRvI pression vector pCDNA3.1/Zeo under a CMV promoter control. was established by stable transfection of EGFRvmI in MCF-7 cells We then transfected the EGFRvIi ribozyme (Rz) into MCF-7/ and appears to express high levels of EGFRvIII and very low EGFRvIII and MCF-7/LCC2 cells. Stable transfectants were selevels of wild-type EGFR. Expression of EGFRvmI in MCF-7 cells lected and denoted as MCF-7/Em/Rz and LCC2/Rz. Northern induces cell proliferation and enhanced tumorigenicity in nude analysis was carried out to evaluate the enzyme activity of this mice.' 2 MCF7/LCC2 is a stepwise in vitro selection of the hor-EGFRvIII ribozyme. As shown in Figure 3a , this novel EGFRvlII mone-independent human breast cancer variant MCF-7 against ribozyme was capable of downregulating EGFRvIm mRNA ex-4-hydroxytamoxifen. MCF7/LCC2 cells appear to express moder-pression significantly in clone MCF-7/Em/RzS5, and completely ate to high levels of wild-type EGFR, but do not express detectable eliminating the EGFRvIIl mRNA expression in clone MCF-7/Em/ levels of EGFRvIm.' 6 The expression of ErbB-2, ErbB-3 and RzS3. In contrast, no effects were observed on wild-type EGFR ErbB-4 levels in MCF-7/EGFRvIII and MCF7/LCC2 are compa-mRNA expression in EGFRvIH Rz transfected LCC2 cells respecrable to the untransfected MCF-7 cells. We therefore used MCF-tively (Fig. 3d) . These results clearly demonstrate EGFRvIII ri-bozyme to be capable of downregulating EGFRvEII mRNA, and A have no effect on wild-type EGFR mRNA intracellularly.
To further characterize the ribozyme effect, we quantitatively (Fig. 3b ). In addition, the level of EGFRvIII phosphorylation is reduced correlating with downregulation of EGFRvIII protein levels in MCF-7/EGFRvIII cells (Fig. 3c) . In contrast, no effect on the ,, 1,
wild-type EGFR expression that was observed in EGFRvHI ribozyme transfected MCF-7/LCC2 cells (Fig. 3e) -These experiments demonstrate the efficacy, efficiency and specificity of this B EGFRvIH ribozyme intracellularly. These data suggest that the constructed EGFRvIII Rz is biologically functional ribozyme. Figure 4a growth of ribozyme-expressing MDA435/LCC6 cells was signifillustrates that EGFRvIlI zibozyme has no effect on the expression icantly inhibited with p < 0.0001 (Table I) . To further confirm the of ErbB-2 and ErbB-3, whereas the EGFRvUI expression was inhibition of tumorigenicity is due to the downregulation of completely abolished. As shown in Figure 4b , EGFRvHI mRNA is EGFRvHI expression in LCC6/Rz cells, we evaluated the EGFRalmost un-detectable in LCC6/RzC1 and LCC6/RzC9 transfectants viii expression of the xenograft tumors. Lysates obtained from compared to LCC6 un-transfected cells. No significant effect was homogenized xenograft tumors of the untransfected MDA435/ observed in clone LCC6/RzC7. LCC6 and ribozyme transfected MDA435/LCC6 cells were subjected to Western blot analysis of EGFRvIH expression with a Downregulation of EGFRvIII in cell lines expressing specific EGFRvIlI monoclonal antibody. As shown in Figure 6 , endogenous egfrviii results in an inhibition of growth rate and EGFRvHII expression was substantially reduced in LCC6/Rz transcolony formation fectants comparing with the un-transfected MDA435ILCC6 cell: The biological effect of downregulation of EGFRvMI expression These results clearly demonstrate that EGFRvIII ribozyme is bioby EGFRvMI-ribozyme in MDA435/LCC6 cells was evaluated by logical active in athymic nude mice, and effectively repressed anchorage-dependent and anchorage-independent growth assays. EGFRvIII expression in breast cancer xenografts. Downregulation of EGFRvIL expression in the MDA435/LCC6 human breast cancer cell line resulted in a significant inhibition of DISCUSSION growth rate compared to their un-transfected cell (p < 0.0001) (Fig. 5a) . Inhibition of colony formation was independent of Epidermal growth factor receptor mutant M (EGFRvMI) is a colony size (p < 0.0001) (Fig. 5b) . In comparison with ribozyme rearrangement, ligand-independent, constitutively active EGFR transfected MCF-7/LCC2 cells, no difference in growth rate on variant, and a tumor-associated receptor. EGFRvm involves an ribozyme transfected MCF-7/LCC2 cells (MCF-7/LCC2/Rz) vs. in-frame deletion between nucleotides 275-1075 in the normal un-transfected MCF-7/LCC2 cells were observed as expected EGFR gene sequence, which corresponds to a deletion of 267 (data not shown). These results indicate a partial reversion of amino acids in the EGFR extracellular domain and distinguishes it transformation by downregulation of EGFRvIII in MDA435/ from full-length EGFR. We evaluated the effects of ribozyme-mediated downregulation of EGFRvIII in an EGFRvIII positive human breast cancer cell line, FimA= 5 -Celf growth assays. a: Anchorage-dependent growth MDA435/LCC6 cells. We observed that the EGFRvflI mRNA and assay. The expression of EGFRvflI ribozyme in MDA435/LCC6 hu-protein was completely abolished. Downregnlation of the EGFRman breast cancer cells resulted in an inhibition of 40% growth rate compared to their un-transfected cell. Cells were plated at a density of viii in LCC6/Rz cells resulted in a reduction of colony formation 3 x l0G cells/ml. Viable cells were counted on Day 1, Day 4 and Day in an anchorage-independent assay compared to untransfected and 7 after seeding. All samples were prepared in triplicate and this assay mock transfected cells. In addition, downregulation of EGFRvIII was repeated three times. b: Anchorage-independent growth assay in MDA435ILCC6 cells significantly inhibited tumor formation in showed that the inhibition of colony formation was independent of athymic nude mice (Table I ). In comparison, no growth effect was colony size. A bottom layer of 1 ml IMEM containing 0.6% agar and observed in ribozyme transfected MCF-7/LC cells, respec-10%FBS was prepared in 35-umn tissue culture dishes. Aftr the ively. This data demonstrated that inhibition of growth is correbot0.8 ml top layer, containing 0.4% Bacto Agar and 5% FBS. The cells lated with the level of downregulation of EGFRvm in these were incubated for about 10 days at 37*C. Colonies larger than 60, ribozymes transfected cells. Reduction of colony formation and 80,100, 120 and 140 um were counted by a cell colony counter. tumorigenicity suggest that EGFRvIII may play a role in All samples were prepared in triplicate. The assay was repeated MDA435/LCC6 cell proliferation. In additioni, this ribozyme was 2 times, capable of downregulation of endogenous level of EGFRvAII in breast cancer cells.
Imbp-
Ribozyme-mediated downregulation of endogenous EGFRvIII in
T,3LE I-AN1-TMOR-ACIvrY oP E3vm-R. E IN LC6
Despite the high frequency of EGFRvI expression in primary 19 To further provide the evidence to support this assumption, nude mice--p < 0.0001.
we evaluated the EGFRvIU expression in MDA435/LCC6 xenografts and MDA435/LCC6 tissue cultured cells. Indeed, we were able to detect substantially higher levels of EGFRvMI expression quently into a ribozyme target codon GUA. We therefore gener-in the lysate obtained from the MDA435/LCC6 xenografts in ated a hammerhead ribozyme targeting this EGFRvMI novel fusion comparison with the lysate obtained from the tissue culture of the junction. Although the flanking sequences of this ribozyme can same breast cancer cell line MDA435/LCC6 by western blotting. bind to both EGFRwt and EGFRvIfl mRNAs, the EGFRwt mRNA EGFRvm ribozyme significantly downregulate the EGFRvIII exdoes not obtain this GUA ribozyme cleavage site. Thus, this pression in ribozyme transfected MDA435/LCC6 xenografts (Fig. ribozyme is only able to cleave the EGFRvIII mRNA but not the 6). These observations further suggest that we have obtained a wild-type EGFR mRNA. We demonstrated that this EGFRvIII biological activated and efficient ribozyme. In addition, we also provide the first evidence that a growth disadvantage for EGFRvII the ribozyme into the tumor cells, the potential utilization of expression occurs in tissue culture. It implies that for some un-ribozyme targeting of EGFRvIJI may constitute a potential future known reason, the EGFRvMII expression is enhanced and triggered promising gene therapeutic approach for a molecular defined subin the in vivo environment during the tumor progression. Figure 5 and Table I were supported by the this anti-EGFRvHI ribozyme will only target the breast cancer Lombardi Canwer Research Center Biomathematics and Biostatistics cells but not the normal cells. Although, its therapeutic use is Core Facility, DHHS/NIH Grant P30-CA-51008. Weýxpress our currently limited by the lack of methodologies to efficiently deliver great appreciation to Dr. ME. Lippman for helpful discussions.
